1. Home
  2. BCG vs SCYX Comparison

BCG vs SCYX Comparison

Compare BCG & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCG
  • SCYX
  • Stock Information
  • Founded
  • BCG 2016
  • SCYX 1999
  • Country
  • BCG United States
  • SCYX United States
  • Employees
  • BCG N/A
  • SCYX N/A
  • Industry
  • BCG
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCG
  • SCYX Health Care
  • Exchange
  • BCG Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • BCG 29.6M
  • SCYX 24.6M
  • IPO Year
  • BCG N/A
  • SCYX 2014
  • Fundamental
  • Price
  • BCG $3.11
  • SCYX $0.69
  • Analyst Decision
  • BCG
  • SCYX Strong Buy
  • Analyst Count
  • BCG 0
  • SCYX 1
  • Target Price
  • BCG N/A
  • SCYX $3.00
  • AVG Volume (30 Days)
  • BCG 2.1M
  • SCYX 642.4K
  • Earning Date
  • BCG 11-13-2025
  • SCYX 11-05-2025
  • Dividend Yield
  • BCG N/A
  • SCYX N/A
  • EPS Growth
  • BCG N/A
  • SCYX N/A
  • EPS
  • BCG 0.04
  • SCYX N/A
  • Revenue
  • BCG $178,203,000.00
  • SCYX $2,932,000.00
  • Revenue This Year
  • BCG N/A
  • SCYX $368.39
  • Revenue Next Year
  • BCG N/A
  • SCYX $123.36
  • P/E Ratio
  • BCG $83.56
  • SCYX N/A
  • Revenue Growth
  • BCG 10.19
  • SCYX N/A
  • 52 Week Low
  • BCG $1.36
  • SCYX $0.57
  • 52 Week High
  • BCG $6.00
  • SCYX $1.49
  • Technical
  • Relative Strength Index (RSI)
  • BCG 68.66
  • SCYX 51.43
  • Support Level
  • BCG $2.14
  • SCYX $0.57
  • Resistance Level
  • BCG $2.68
  • SCYX $0.73
  • Average True Range (ATR)
  • BCG 0.39
  • SCYX 0.06
  • MACD
  • BCG 0.17
  • SCYX 0.02
  • Stochastic Oscillator
  • BCG 78.68
  • SCYX 71.15

About BCG Binah Capital Group Inc. Common Stock

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: